Department of Orthopaedic Surgery, Orthopedics Oncology Institute of Chinese PLA, Tangdu Hospital, Xi'an, China.
Cancer Biol Ther. 2011 Jan 15;11(2):287-92. doi: 10.4161/cbt.11.2.13966.
to screen the pulmonary metastasis-associated molecules of Osteosarcoma and evaluate their functions concerning prognosis prediction.
cDNA microarray analysis has been applied to 2 pairs of osteosarcoma cell sublines with differential metastatic potentials to the lung. Immunohistochemistry and survival analysis have been performed to clinical samples of osteosarcoma patients.
Analysis detected 484 differentially expressed genes between the high metastatic subline, F5M2, and the low metastatic subline, F4. There were 1257 genes differentially expressed between newly established high-metastatic sublines named Saos-2M2 and its parental cell line Saos-2. Furthermore, 16 commonly up-regulated genes and 5 commonly down-regulated genes were identified by clustering analysis. EREG and CHST2, two genes not previously described in osteosarcoma, were finally seen to be differentially expressed in all examined osteosarcoma cell lines and in samples between the different prognosis sample groups. Survival analysis also confirmed these two molecules could be used to predict the outcome of OSA patients.
This work represents a rationale approach to the evaluation of microarray data and will be useful to identify genes that may be causally associated with metastasis. EREG and CHST2 will be likely considered as clinical molecular markers to predict the outcome of OSA.
筛选骨肉瘤肺转移相关分子,并评估其对预后预测的功能。
采用 cDNA 微阵列分析技术,对具有不同肺转移潜能的 2 对骨肉瘤细胞亚系进行分析。对骨肉瘤患者的临床样本进行免疫组织化学和生存分析。
分析发现高转移亚系 F5M2 与低转移亚系 F4 之间有 484 个差异表达基因。新建立的高转移亚系 Saos-2M2 及其亲本细胞系 Saos-2 之间有 1257 个差异表达基因。通过聚类分析,还鉴定出 16 个共同上调基因和 5 个共同下调基因。此前未在骨肉瘤中描述的 EREG 和 CHST2 两个基因最终在所有检测的骨肉瘤细胞系以及不同预后样本组之间的样本中均显示出差异表达。生存分析也证实这两个分子可用于预测 OSA 患者的预后。
这项工作代表了一种评估微阵列数据的合理方法,将有助于识别可能与转移有因果关系的基因。EREG 和 CHST2 将可能被视为预测 OSA 预后的临床分子标志物。